<div class="top_bar" layout="row" layout-align="space-between center">
  <md-button back-button style="float:left; color:green; font-weight:bold;"><i class="fa fa-angle-left" aria-hidden="true"></i> Back</md-button>
  <div>
   <md-button style="color:white; background-color:rgb(53,121,42)!important;font-size:13px; font-weight:bold; " href="#!/patient_landing"> Join trial </md-button>
  </div>
</div>
<md-content class="mytrials_page " style="background-color: #ececec !important" layout="column" layout-align="space-between center">
 <div>
<div class="my_trail_card_head p-15 bg-white "><a href="">Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)</a></div>
<div layout="row" layout-align="space-between stretch" class="bg_white my_trial_cardsec">

<div class="p-15 tile" flex="25" layout="column" layout-align="center center">
  <i class="fa fa-calendar-plus-o fa-3x" aria-hidden="true"></i>
  <h6>Start Date</h6>
  <div><h2><span>June 30,</span>  <span>12PM</span> </h2></div>
</div>

<div class="p-15 tile" flex="25" layout="column" layout-align="center center">
    <i class="fa fa-medkit fa-3x" aria-hidden="true"></i>
   <h6>Sponsors</h6>
   <div><h2><span>AstraZeneca</span></h2></div>
</div>

<div class="p-15 tile" flex="25" layout="column" layout-align="center center">
    <i class="fa fa-hourglass-half fa-3x" aria-hidden="true"></i>
   <h6>Status</h6>
   <div><h2><span>Recruiting</span></h2></div>
</div>

<div class="p-15 tile" flex="25" layout="column" layout-align="center center">
  <a href="#!/community_page" > <i class="fa fa-users fa-3x" aria-hidden="true"></i>
  <h6>Trend Community</h6>
  <div><h2><span>Cardiovascular</span></h2></div></a>
</div>

<!-- <div class="p-15 tile" flex="20" layout="column" layout-align="center center">
  <i class="fa fa-calendar-plus-o fa-3x" aria-hidden="true"></i>
  <h6>Next appointment</h6>
  <div><h2>June <span>30</span> '16 <span>12PM</span> EST</h2></div>
</div> -->

</div>


<div layout="column" layout-align="space-between stretch" class="my_trial_cardsec my_trial_notification ">



<div class="tile p-t-15" flex="30" layout="column" layout-align="center stretch">
<h2 class="act_head">Trial Details</h2>
 <div class="force-overflow style-1 bg_white p-15 m-r-3 m-b-3">
<div layout="row" layout-align="space-between center" style="width:100%">
                                  
                                  <h3>Purpose</h3>
                                </div>
                                <div layout="column" style="width:100%">
                                    <p ng-hide="showpurpose" style="font-size:14px ; letter-spacing: normal;">The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.
                                    </p>
                                </div>
 </div>

  <div class="force-overflow style-1 bg_white p-15 m-r-3 m-b-3 ">
<div layout="column" style="width:100%">
                                <table class="" cellspacing="0" cellpadding="5" width="100%"  >
                                                <tbody >
                                                    <tr align="left">
                                                        <th style="padding: 5px 7px">
                                                            <span class="popup" >Condition</span>
                                                        </th>
                                                        <th style="padding: 5px 7px">
                                                            Intervention
                                                        </th>
                                                        <th style="padding: 5px 7px">
                                                            Phase
                                                        </th>
                                                    </tr>
                                                    <tr>
                                                        <td>
                                                            Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
                                                        </td>
                                                        <td>
                                                            Drug: EpanovaÂ® (omega-3 carboxylic acids)
                                                        </td>
                                                        <td>
                                                            Phase 3
                                                        </td>
                                                    </tr>
                                                </tbody>
                                            </table>
                                            </div>
 </div>

  <div class="force-overflow style-1 bg_white p-15 m-r-3 m-b-3">
<div layout="row" layout-align="space-between center" style="width:100%">
                                  
                                  <h3>Outcome Measures</h3>
                                </div>
                                <div layout="column" style="width:100%">
                                    <div class="expandable">
                                            <div class="section_4 p-15" layout="row" layout-align="space-around start">
                                                <span class="p-r-15" style="width:50%">
                                                    <h5>Primary Outcome Measures</h5>
                                                    <ul>
                                                        <li>The primary outcome measure is the time to the first occurrence of any component of the composite of MACE. [ Time Frame: Patients will remain in the study until the required number of MACE has occurred. We anticipate that patients will be in the study for up to 5 years. ] [ Designated as safety issue: No ]</li>
                                                        <li>MACE components include: cardiovascular death, nonfatal MI, nonfatal stroke, emergent/elective coronary revascularization, or hospitalization for unstable angina.</li>
                                                    </ul>
                                                </span>
                                                <span style="width:50%">
                                                    <h5>Secondary Outcome Measures</h5>
                                                    <ul>
                                                        <li>The composite measure of CV events that include the first occurrence of cardiovascular death, non-fatal MI and non-fatal stroke. [ Time Frame: We anticipate that patients will be in the study for up to 5 years. Same for all outcome measures. ] [ Designated as safety issue: No ]
                                                            The secondary outcome measures will be analyzed the same as outlined above for the primary outcome measures.
                                                        </li>
                                                        <li>The composite measure of coronary events that include the first occurrence of cardiac death. [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]</li>
                                                        <li>The composite measure of coronary events that include the first occurrence of cardiac death ( including death due to acute myocardial infarction, sudden cardiac death and death due to cardiovascular procedures), nonfatal MI, emergent/elective coronary revascularization, or hospitalization for unstable angina.</li>
                                                        <li>The first occurrence of individual components of MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, emergent/elective coronary revascularization, or hospitalization for unstable angina. [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
                                                            Time to CV death [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
                                                            Cardiovascular death includes death resulting from: an acute MI, sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes.
                                                        </li>
                                                    </ul>
                                                </span>
                                            </div>
                                        </div>
                                </div>
 </div>


  <div class="force-overflow style-1 bg_white p-15 m-r-3 m-b-3">
<div layout="row" layout-align="space-between center" style="width:100%">
                                  
                                  <h3>Arms</h3>
                                </div>
                                <div layout="column" style="width:100%">
                                 <div class="expandable">
                                            
                                            <div class="exp_detail" style="border-bottom: none; padding-bottom: 10px">
                                                <div class="">
                                                    <div layout="row">
                                                        <div flex>
                                                            <h5>Experimental : EPANOVA</h5>
                                                            <div class="sub_answers">Epanova + statin, once daily</div>
                                                        </div>
                                                        <div flex>
                                                            <h5>Interventions: EpanovaÂ® (omega-3 carboxylic acids)</h5>
                                                            <div class="sub_answers">Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
                                                                Other Name: omega-3 carboxylic acids
                                                            </div>
                                                        </div>
                                                    </div>
                                                </div>
                                            </div>
                                           
                                            <div class="exp_detail" style="border-bottom: none; padding-bottom: 10px">
                                                <div class="">
                                                    <div layout="row">
                                                        <div flex>
                                                            <h5>Active Comparator : Corn oil</h5>
                                                            <div class="sub_answers">Corn oil + Statin</div>
                                                        </div>
                                                        <div flex>
                                                            <h5>Interventions: corn oil control</h5>
                                                            <div class="sub_answers">corn oil control arm</div>
                                                        </div>
                                                    </div>
                                                </div>
                                                <div style="text-align:center !important; ">
                                                    <md-button ng-show="add_arm_1" style="color:white; background-color:rgb(53,121,42)!important;font-size:13px; font-weight:bold; "> Add Arm </md-button>
                                                </div>
                                            </div>
                                        </div>
                                </div>
 </div>
  
   <div class="force-overflow style-1 bg_white p-15 m-r-3 m-b-3">
<div layout="row" layout-align="space-between center" style="width:100%">
                                  
                                  <h3>Contact</h3>
                                </div>
                                <div style="width:100%" layout="row" layout-align="space-between center">
                                  
                                    <p style="font-size:14px ; letter-spacing: normal;">AstraZeneca Clinical Study Information Center   

                                    </p>
                                    <p style="font-size:14px ; letter-spacing: normal;">1-877-240-9479  </p><p style="font-size:14px ; letter-spacing: normal;">information.center@astrazeneca.com  </p>
                                </div>
                                <div layout="column" style="width:100%">
                                  <h5>Sponsors and Collaborators</h5>
                                  <div layout="row" layout-align="space-between center"  style="font-size:14px ; letter-spacing: normal;">
                                  <p><strong>AstraZeneca</strong></p>
                                  <p><strong>Cleveland Clinic Coordinating Center for Clinical Research (C5R)</strong></p>
                                  <p><strong>Quintiles, Inc.</strong></p>
                                  </div>
                                   
                                </div>
                                 <div layout="column" style="width:100%; margin-top: 10px">
                                  <h5>Principal Investigators</h5>
                                  <div layout="row" layout-align="space-between center"  style="font-size:14px ; letter-spacing: normal;">
                                  <p><strong>Steven Nissen</strong>, MD The Cleveland Clinic</p>
                                  <p><strong>Michael Lincoff</strong>, MD The Cleveland Clinic
                                  <p><strong>Stephen Nicholls</strong>, MD  Adelaide Clinical Research</p>
                                  </div>
                                   
                                </div>
 </div>
<div class="force-overflow style-1 bg_white p-15 m-r-3 m-b-3">
<div layout="column" layout-align="center center" style="width:100%">
 <md-button style="color:white; background-color:rgb(53,121,42)!important;font-size:13px;padding: 10px; font-weight:bold; width:250px" href="#!/patient_landing"> Join trial </md-button>
  <h5>Share</h5>
 <div layout="row" layout-align="center center" style="width:100%">
   <i class="fa fa-facebook-square fa-2x m-r-3 p-10" aria-hidden="true" style="cursor: pointer;"></i><i class="fa fa-twitter-square m-r-3 fa-2x p-10" aria-hidden="true" style="cursor: pointer;"></i><i class="fa fa-google-plus-square fa-2x m-r-3 p-10" aria-hidden="true" style="cursor: pointer;"></i>

 </div>

</div>
</div>

</div>
</div>
</div>
<div class="footer">
   <div class="bottom_text" layout="row" layout-align="center center">
    <div> About Clinical Trials </div>
    <div> About Quest </div>
    <div> Contact Us </div>
    <div> Privacy Policy </div>
  </div>
  <div class="bottom_last_text" layout="row" layout-align="center center">Quest Diagnostics IncorporatedÂ© 2000-2017. All rights reserved.</div>
</div>
